The effect of intracavernosal growth differentiation factor‐5 therapy in a rat model of cavernosal nerve injury
- 2 August 2006
- journal article
- Published by Wiley in BJU International
- Vol. 98 (3), 632-636
- https://doi.org/10.1111/j.1464-410x.2006.06375.x
Abstract
To determine whether the intracavernosal application of growth differentiation factor-5 (GDF-5) influences nerve regeneration and erectile function after cavernosal nerve injury in a rat model. Thirty-two male Sprague-Dawley rats were randomly divided into four equal groups: eight had a sham operation (uninjured controls), while 24 had bilateral cavernosal nerve crush. The crush-injury groups were treated at the time of injury with an impregnated collagen sponge implanted into the right corpus cavernosum. The sponge contained no GDF-5 (injured controls), 2 microg (low concentration), or 20 microg GDF-5 (high concentration). Erectile function was assessed by cavernosal nerve electrostimulation at 8 weeks. Midshaft penile tissue samples were histochemically evaluated for neuronal nitric oxide synthase (nNOS)-containing fibres in the dorsal penile nerve. There was no erectile dysfunction in the uninjured control group, as shown by a mean (sem) maximal increase in intracavernosal pressure (ICP) of 149.5 (17.0) cmH(2)O on stimulation. By comparison, the ICP decreased in the injured control group, by 21.3 (6.7) cmH(2)O. After cavernosal nerve injury, the recovery of erectile function was greatest in the low-concentration GDF-5 group; the maximum ICP increase was 40.8 (13.3) cmH(2)O, vs 24.3 (5.9) cmH(2)O for 20 microg GDF-5. Histologically, the low-concentration group had significantly more nNOS-containing nerve fibres, at 163 (24.7), than the high-concentration group, at 76 (17.3), or injured controls, at 67 (23.8). By contrast, the uninjured controls had a mean of 538 (40.6) nerve fibres in the dorsal nerve. Bilateral cavernosal nerve crush resulted in erectile dysfunction with accompanying neurological changes in the rat. The intracavernosal application of GDF-5 enhanced the recovery of erectile function and n-NOS nerve preservation, with a 2-microg dose giving the most promising results.This publication has 29 references indexed in Scilit:
- Combination of engineered neural cell adhesion molecules and GDF-5 for improved neurite extension in nerve guide conceptsBiomaterials, 2006
- Open Retropubic Nerve-Sparing Radical ProstatectomyEuropean Urology, 2006
- The role of growth/differentiation factor 5 (GDF5) in the induction and survival of midbrain dopaminergic neurones: relevance to Parkinson's disease treatmentJournal of Anatomy, 2005
- The additive erectile recovery effect of brain‐derived neurotrophic factor combined with vascular endothelial growth factor in a rat model of neurogenic impotenceBJU International, 2005
- The effect of neural embryonic stem cell therapy in a rat model of cavernosal nerve injuryBJU International, 2004
- The Effect of Vascular Endothelial Growth Factor and Adeno-Associated Virus Mediated Brain Derived Neurotrophic Factor on Neurogenic and Vasculogenic Erectile Dysfunction Induced by HyperlipidemiaJournal of Urology, 2003
- THE EFFECT OF ADENO-ASSOCIATED VIRUS MEDIATED BRAIN DERIVED NEUROTROPHIC FACTOR IN AN ANIMAL MODEL OF NEUROGENIC IMPOTENCEJournal of Urology, 2001
- Regeneration of Nitric Oxide Synthase-Containing Nerves After Cavernous Nerve Neurotomy in the RatJournal of Urology, 1995
- Limb alterations in brachypodism mice due to mutations in a new member of the TGFβ-superfamilyNature, 1994
- Radical Prostatectomy and Cystoprostatectomy with Preservation of Potency. Results Using a New Nerve‐sparing TechniqueBJU International, 1984